

Express Mail No.: EM 325 961 170 US**PENNIE & EDMONDS LLP**COUNSELLORS AT LAW
1155 Avenue of the Americas
New York, N.Y. 10036-2711
(212) 790-909067136 U.S. PTO
08/829558ATTORNEY DOCKET NO. 8105-009Date March 28, 1997Assistant Commissioner for Patents
Box PATENT APPLICATION
Washington, D.C. 20231

Sir:

The following utility patent application is enclosed for filing:

Applicant(s): Daniel Meruelo
Kouichi OhnoExecuted on: March 28, 1997
March 28, 1997

Title of Invention: VIRAL VECTORS HAVING CHIMERIC ENVELOPE PROTEINS CONTAINING THE IgG-BINDING DOMAIN OF PROTEIN A

Pages of Specification 35 + Abstract

Sheets of Drawings 6

PATENT APPLICATION FEE VALUE

TYPE	NO. FILED	LESS	EXTRA	EXTRA RATE	FEE
Total Claims	47	-20	27	\$22.00 each	594.00
Independent	5	-3	2	\$80.00 each	160.00
Minimum Fee					770.00
Multiple Dependency Fee If Applicable (\$260.00)					
Total					1,524.00
50% Reduction for Independent Inventor, Nonprofit Organization or Small Business Concern (a verified statement as to the applicant's status is attached)					-
Total Filing Fee					\$ 1,524.00

Priority of application no. filed on in is claimed under 35 U.S.C. § 119.

Please charge the required fee to Pennie & Edmonds LLP Deposit Account No. 16-1150. A copy of this sheet is enclosed.

Respectfully submitted,

by Brian M. Poissant Reg. No. 36,581

Brian M. Poissant

28,462
(Reg. No.)

PENNIE & EDMONDS LLP

Enclosure

This form is not for use with re-issue, design or plant patent applications.



VIRAL VECTORS HAVING CHIMERIC ENVELOPE PROTEINS
CONTAINING THE IgG-BINDING DOMAIN OF PROTEIN A

TABLE OF CONTENTS

	Page
5 1. FIELD OF THE INVENTION	- 1 -
2. BACKGROUND OF THE INVENTION	- 1 -
2.1. Use of Amphotropic and Ecotropic Retrovirus Vectors	- 2 -
10 2.2. Known Viral Vector Complexes to Transduce Target Cells	- 4 -
2.3. Use of Sindbis Virus Vectors	- 5 -
3. SUMMARY OF THE INVENTION	- 8 -
4. BRIEF DESCRIPTION OF THE FIGURES.	- 8 -
15 5. DETAILED DESCRIPTION OF THE INVENTION	- 11 -
6. EXAMPLES	- 15 -
6.1. Example 1:	- 15 -
6.1.1. Plasmids and Cell Line.	- 16 -
6.1.2. Construction of chimeric env gene.	- 16 -
20 6.1.3. Cell transfection and virus production.	- 17 -
6.1.4. Immunoblot assay.	- 17 -
6.1.6. Results	- 18 -
6.1.7. Discussion	- 20 -
6.2. Example 2:	- 21 -
25 6.2.2. Construction of protein A-envelope Sindbis virus helper plasmid.	- 21 -
6.2.3. Expression and incorporation of chimeric envelopes into virions.	- 22 -
6.2.4. Infection with viruses carrying mutant envelopes.	- 23 -
30 6.2.5. Discussion	- 25 -
6.2.6. Experimental protocol	- 28 -
7. DEPOSIT OF MICROORGANISMS	- 31 -
35 8. SEQUENCE LISTING	- 33 -



BOX
SERIALS
H

VIRAL VECTORS HAVING CHIMERIC ENVELOPE PROTEINS CONTAINING THE IgG-BINDING DOMAIN OF PROTEIN A

1. FIELD OF THE INVENTION

5 The invention involves viral vectors that can be used to transduce a target cell, i.e., to introduce genetic material into the cell. The targets of interest are eukaryotic cells and particularly human cells. The transduction can be done *in vivo* or *in vitro*. More particularly the invention
10 concerns viral vectors that have chimeric envelope proteins and contain the IgG-binding domain of protein A. These vectors when used in conjunction with antibodies targeting a particular cell are particularly useful for gene therapy.

2. BACKGROUND OF THE INVENTION

15

A variety of viral based vectors have been employed to transfer and to express a gene of interest into a eukaryotic target cell. Recombinant DNA techniques are used to replace one or more of the genes of the virus with the gene of
20 interest operably linked to a promoter that is functional in the target cell. The construct, termed a viral vector, infects the target cell, using the physiological infective "machinery" of the virus, and expresses the gene of interest instead of the viral genes. Because not all the genes of the
25 virus are present in the vector, infection of the target by the vector does not produce viral particles. Viruses that have been used to infect human or mammalian target cells include herpes virus, adenovirus, adeno-associated virus and derivatives of leukemia-type retroviruses. Among the
30 retroviruses of particular interest in the transduction of cells of human origin are constructs based on amphotropic retroviruses.

35

2.1. Use of Amphotropic and Ecotropic Retrovirus Vectors

Retroviruses are particularly well suited for transduction of eukaryotic cells. The advantages of a vector based this type of virus include its integration into the genome of the target cell so that the progeny of the transduced cell express the gene of interest. Secondly, there are well developed techniques to produce a stock of infectious vector particles that do not cause the production of viral particles in the transduced target cell. Lastly, the production and purification of stocks vector particles having titers of 10^6 TCIU/ml can be accomplished.

One disadvantage of the use of retroviral vectors is that there is presently no practical general, method whereby a particular tissue or cell type of interest can be specifically transduced. Previous efforts to this end have included surgical procedures to limit to specific organs the physical distribution of the viral vector particles (Ferry, N. et al., 1991, *Proc. Natl. Acad. Sci.* **88**:8377). Alternatively, practitioners have taken advantage of the fact that type C retroviruses only infect dividing cells. Thus, a population of cells, e.g., bone marrow cells, was removed from a subject and cultured *ex vivo* in the presence of growth factors specific for the specific target cell which, thus, comprises most of dividing cells in the culture. See, e.g., Wilson, J.M. et al., 1990, *Proc. Natl. Acad. Sci.* **87**:439-47; Ohashi, T. et al., 1992, *Proc. Natl. Acad. Sci.* **89**:11332-36. After transduction the dividing cells must be harvested and, for many purposes, reimplanted into the subject. The technical difficulties of the *ex vivo* culture technique combined with the unavailability of growth factors of specific for some types of cells have limited the application of this approach.

A second difficulty presented by the use retroviral based vectors is that a recombination may occur between sequences of vector and an endogenous retrovirus. Such

recombination can give rise to a replication competent virus that can cause the production of infectious particles by the target cell. In contrast to herpes virus or adenovirus infection, retroviral infections are not necessarily self-limiting.

Notwithstanding these difficulties, retrovirus vectors based on amphotropic murine leukemia retroviruses that infect human cells, have been approved for use in human gene therapy of certain diseases, for example adenosine deaminase and low density lipoprotein receptor deficiencies and Gaucher's Disease. See, e.g., Miller A.D., 1992, *Nature* 357:455; Anderson, W.F., 1992, *Science* 256:808; and Crystal, R.G., 1995, *Science* 270:404-410.

One approach to overcoming the limitations of using amphotropic retrovirus vectors in human cells has been to mutate the gene encoding the protein on the viral surface that determines the specificity of infection of the virus, the gp70 protein. Using recombinant DNA technology a "mutant" virus is constructed that has had small regions of the gp70 sequence replaced by predetermined sequences. The limits of this approach are set by the requirement for knowledge of the sequence that will enable infection of the target of interest. However, when this knowledge was available, the anticipated alteration in viral specificity has been observed (Valsesia-Wittmann, S., 1994, *J. Virol.* 68:4609-19).

Retrovirus vectors are the most efficient tools available today to stably transduce genes into the genomes of vertebrate cells. Murine leukemia retrovirus (MLV)-based vectors commonly used for gene transfer are classified on the basis of their host range as either ecotropic or amphotropic. Murine ecotropic virions can only infect mouse or rat cells, but murine amphotropic viruses can infect cells of most species, including human cells. Because of their ability to infect such a broad spectrum of cells, a major drawback to the use of amphotropic virus vectors is the fact that these vectors lack target-cell specificity.

Several attempts to alter the host range of retroviruses have been reported to date. Recently, direct modifications of the envelope protein of murine leukemia virus (MLV) have been shown to redirect the viral tropism. A recombinant virus containing a fragment encoding a single Fv antibody chain at the N terminal region of the MLV env gene has been shown to recognize the corresponding epitopes and infect human cells (Russell, S.J. et al., 1993, *Nucleic Acids Res.* 21:1081-1085; Somia, N.V. et al., 1995, *Proc. Natl. Acad. Sci. USA* 92:7570-7574; Marin, M. et al., 1996, *J. Virol.* 70:2957-2962). Kasahara et al. have made a chimeric ecotropic virus containing an erythropoietin-envelope fusion protein (Kasahara, N. et al., 1994, *Science* 266:1373-1376). This chimeric virus has been shown to infect human cells bearing the erythropoietin receptor. However, this type of approach suffers from at least two limitations. First, each targetable vector must be constructed *de novo*. It is unlikely that the incorporation of different targeting elements in the envelope of the virus can always be achieved with equal success and without reducing the virus titers than can be obtained. Second, virions constructed to directly bind to specific targets in human cells are intrinsically unsafe, as wild-type recombinants could produce potentially harmful effects patients treated with such vectors. By contrast, virions constructed as outlined in this manuscript are uninfecious to human cells in the absence of an accompanying targeting reagent, such as a mAb, which is produced separately and only provided in conjunction with the virus at a convenient time.

30

2.2. Known Viral Vector Complexes to Transduce Target Cells

An alternative to altering the specificity of binding of the gp70 protein itself is to employ a second, novel structure that binds or is bonded to both the viral particle and to the target cell. In one example of this approach,

35

lactose molecules were covalently coupled, by a non-specific reaction, to the envelope proteins of an ecotropic retrovirus, which does not normally infect human cells. A human hepatocellular carcinoma that was known to have
5 receptors for lactose-containing proteins was found to be susceptible to transduction by this vector complex, although the integration of the transduced gene of interest in the target cell chromosome was not directly demonstrated (Neda, H. et al., 1991, *J. Biol. Chem.* **266**:14143). No evidence of
10 expression was observed in a hepatocellular carcinoma that lacked the lactose specific receptor. The method of Neda results in a variable number of binding sites for the exposed acceptor on the target cell, attached to each derivatized or bound envelope protein and, of course, is limited to the case
15 wherein the target cell has a lactose receptor.

Another approach to targeting is the use of adapter molecules involved an adapter that was not covalently coupled to the vector. The use of this type of adapter has been attempted by Roux and his colleagues, who have published
20 several reports that relate to this strategy (Patent Publication FR 2,649,119 to Piecheczyk, January 4, 1991; Roux P. et al., 1989, *Proc. Natl. Acad. Sci.* **86**:9079-83; Etienne-Julan, M. et al., 1992, *J. Gen. Virol.* **73**:3251-55). Roux and colleagues have constructed adapters from two types of
25 proteins, both typically antibodies, by biotinylating the proteins and utilizing avidin or streptavidin tetramer, a protein which binds four biotin molecules, to form aggregates of up to four of the biotinylated proteins.

A better approach is described in U.S. Serial No.
30 08/363,137, filed December 23, 1994, Meruelo et al., the contents of which are hereby incorporated by reference into this patent application. Meruelo et al. describe viral complexes and methods of use to prepare pre-formed adaptors and linkers suitable for gen therapy. They are particularly
35 well-suited for retroviral systems.

2.3. Use of Sindbis Virus Vectors

Sindbis virus, a member of the *Alphavirus* genus, has received considerable attention for use as virus-based expression vectors. Many properties of alphavirus vectors make them a desirable alternative to other virus-derived vector systems being developed, including rapid engineering of expression constructs, production of high-titered stocks of infectious particles, infection of nondividing cells, and high levels of expression (Strauss, J. H. et al., 1994, *Microbiol. Rev.* **58**:491-562; Liljeström, P. et al., 1991, *Biotechnology* **9**:1356-1361; Bredenbeek, P. et al., 1992, *Semin. Virol.* **3**:297-310; Xiong, C. et al., 1993, *Science* **243**:1188-1191). However, a major drawback to the use of Sindbis virus vectors is the fact that these vectors lack target-cell specificity. For mammalian cells, at least one Sindbis virus receptor is a protein previously identified as the high-affinity laminin receptor, whose wide distribution and highly conserved nature may be in part responsible for the broad host range of the virus (Strauss, J.H. et al. 1994; Wang, K.-S. et al., 1992, *J. Virol.* **66**:4992-5001). It is desirable to alter the tropism of the Sindbis virus vectors to permit gene delivery specifically to certain target cell types. This will require both the ablation of endogenous viral tropism and the introduction of novel tropism. In the mature Sindbis virus virion, a plus-stranded viral genome RNA is complexed with capsid protein C to form icosahedral nucleocapsid that is surrounded by lipid bilayer in which two integral membrane glycoproteins, E1 and E2 are embedded (Strauss, J.H. et al., 1994). Although E1 and E2 form heterodimer that functions as a unit, the E2 domain appears to be particularly important for binding to cells. Monoclonal antibodies (mAbs) capable of neutralizing virus infectivity are usually E2 specific, and mutations in E2, rather than E1, are more often associated with altered host range and virulence (Stanley, J. et al., 1985, *J. Virol.* **56**:110-119; Olmsted, R.A. et al., 1986, *Virology* **148**:245-254; Polo, J.M. et al., 1988, *J. Virol.* **62**:2124-2133; Lustig, S. et al., 1988 *J. Virol.* **62**:2329-2336). Recently, a Sindbis

virus mutant was identified which contained an insertion in E2 and exhibited defective binding to mammalian cells. This mutant is expected to be useful for development of targetable Sindbis virus vectors (Dubuisson, J. et al., 1993, *J. Virol.* 5 67:3363-3374).

Grieve et al. (International Publication No. WO 94/17813 published August 18, 1994, "Defective Sindbis Virus Vectors That Express *Toxoplasma Gondii* P30 Antigens") report the use of defective sindbis viral vectors to protect mammals from
10 protozoan parasites, helminth parasites, ectoparasites, fungi, bacteria and viruses, the contents of which are hereby incorporated by reference. Garoff et al. (International Publication No. WO 92/10578 published June 25, 1992, "DNA Expression Systems Based On Alphaviruses") describe the use
15 of alphaviruses to express protein sequences for immunization or protein production, the contents of which are hereby incorporated by reference. Davis et al. (U. S. Patent No. 5,185,440 issued February 9, 1993, entitled "cDNA Clone Coding For Venezuelan Equine Encephalitis [(VEE)] Virus And
20 Attenuating Mutations Thereof) disclose cDNA encoding VEE and methods of preparing attenuated Togaviruses, the contents of which are hereby incorporated by reference. Huang et al. (U. S. Patent No. 5,217,879 issued June 8, 1993, entitled "Infectious Sindbis Virus Vectors") describe infectious
25 Sindbis virus vectors with heterologous sequences inserted into the structural region of the genome, the contents of which are hereby incorporated by reference. Schlessinger et al. (U. S. Patent No. 5,091,309 issued February 25, 1992, entitled "Sindbis Virus Vectors") describe RNA vectors based
30 on the Sindbis Defective Interfering (DI) particles with heterologous sequences inserted, the contents of which are hereby incorporated by reference. Dalemans et al. (International Publication No. WO 95/27069 published October 12, 1995, "Alpha Virus RNA As Carrier For Vaccines") report
35 the medical use of alphaviruses, specifically the Semliki Forest Virus, to delivery exogenous RNA encoding a antigenic epitope or determinant, the contents of which are hereby

incorporated by reference. Dubensky et al., International Publication No. WO 95/07994 published March 23, 1995, "Recombinant Alphavirus Vectors" describe recombinant retroviral alphavirus vectors for delivery of heterologous genes to target cells, the contents of which are hereby incorporated by reference. Sjöberg et al., International Publication No. WO 95/31565 published November 23, 1995, "Alphavirus Expression Vector" disclose vectors for enhanced expression of heterologous sequences downstream from an alphavirus base sequence, the contents of which are hereby incorporated by reference. Liljeström et al., International Publication No. WO 95/27044 published October 12, 1995, "Alphavirus cDNA Vectors" describe a cDNA construct that may be introduced and transcribed in animal or human cells, the contents of which are hereby incorporated by reference.

3. SUMMARY OF THE INVENTION

The invention concerns viral vectors and their use. Specifically, the invention is concerned with viruses having a protein on the viral particle surface that is a chimeric protein comprising a viral envelope protein and an IgG-binding domain of protein A. Because protein A binds to an Fc region of antibody, these chimeric proteins enable one to use an antibody to target the viral particle to a desired cell to which the antibody binds and not to a cell to which the antibody does not bind.

4. BRIEF DESCRIPTION OF THE FIGURES.

Figure 1. A. Schematic representation of expression constructs. p439 is the SV40-based expression vector including wild-type Mo-MLV envelope gene. Plasmid p439-ZZ was constructed by replacement of the Mo-MLV env gene with synthetic IgG-binding part (ZZ) of protein A between unique restriction sites *Bst* EII and *Bam* HI in p439 vector in the presence of compatible linker-spacer. See Materials and Methods for details of construction. Abbreviations: LTR, long

terminal repeat ; SV40P, SV40 early enhancer/promoter; L, leader sequence; SU, surface protein; TM, transmembrane protein; ZZ, synthetic protein A; L/S, Linker-Spacer; p(A), polyadenylation signal. B. Immunoblot analysis of lysates
 5 from COS-7 cells transiently transfected with p439 and p439-ZZ. Lane 1 and 2 were stained with a SU antiserum followed by HRP-conjugated rabbit anti-goat IgG. Lane 3 and 4 were stained with HRP-conjugated rabbit IgG for detection of protein A.

10

Figure 2. A. Immunoblot analysis of virions produced by ψ 2 and ψ 2-ZZ10 packaging cells. Lane 1 and 2 were stained with a SU antiserum followed by HRP-conjugated rabbit anti-goat IgG. Lane 3 and 4 were stained with HRP-conjugated
 15 rabbit IgG for detection of protein A. B. ELISA for detection of IgG-binding activity of chimeric virus produced by ψ 2-ZZ10 cells. Open circle, virions from ψ 2; closed circle, virions from ψ 2-ZZ10. Results are average of triplicate determinants.

20

Figure 3. (A) Schematic strategy for retargeting an Sindbis virus vector. A wild-type Sindbis virus (left) binds to mammalian cells via its surface receptor which is known to be highly conserved across species. A recombinant Sindbis virus
 25 displaying IgG-binding domain of protein A (right) should permit binding to a novel target molecule on the cell surface when used with a corresponding monoclonal antibody (mAb). (B) Schematic representation of recombinant helper constructs and a SinRep/LacZ expression vector. DH-BB is a parental helper
 30 plasmid which contains the genes for the structural proteins (capsid, E3, E2, 6K and E1) required for packaging of the Sindbis viral genome. DH-BB-Bst was constructed by introduction of a cloning site (*Bst*EII) into the E2 glycoprotein between amino acids 71 and 74. The synthetic
 35 IgG-binding domain (ZZ) of protein A was inserted at *Bst*EII in the DH-BB-Bst helper plasmid and DH-BB-ZZ was obtained. SinRep/LacZ, is a Sindbis virus-based expression vector which

contains the packaging signal, nonstructural protein genes for replicating the RNA transcript and lacZ gene.

Abbreviations: P_{SG}, Sindbis viral subgenomic promoter; C, capsid; nsP1-4, nonstructural protein genes 1 - 4; ZZ, 5 synthetic IgG-binding domain of protein A; p(A), polyadenylation signal.

Figure 4. Detection of Sindbis viral structural protein components and a recombinant envelope. Cell lysates (A) from 10 BHK cells transfected with helper RNA and pellets of viral particles (B and C) produced from these cells were subjected to SDS-PAGE analysis. After transferring to a nitrocellulose filter, viral proteins were stained with diluted anti-Sindbis virus mouse immune ascitic fluid to detect all structural 15 components (A and B) or with HRP-conjugated goat anti-mouse IgG to detect protein A-envelope chimeric protein (C). In each panel, lane 1, DH-BB; lane 2, DH-BB-Bst; lane 3, DH-BB-ZZ.

20 **Figure 5.** Infection of HeLa and HeLa-CD4⁺ cells with recombinant Sindbis virus derived from DH-BB-ZZ helper RNA which is transducing the bacterial lacZ gene. Viral supernatants (200 μ l) were preincubated without or with anti-CD4 mAb (0.5 μ g/ml) at room temperature for 1 hour, and added 25 to each cells (2×10^5) in 6-well plates. After 1 hour incubation at room temperature, cells were washed with PBS and incubated in growth medium for 24 hours. Viral infection was evaluated by X-Gal Staining.

30 **Figure 6.** Antibody-dependent infectivities of recombinant Sindbis virus particles on A431 and U87MG cells. Viral supernatants (20 μ l for DH-BB, 500 μ l for DH-BB-ZZ) were preincubated without or with anti-EGFR mAb (0.5 μ g/ml) at room temperature for 1 hour, and added to cells (2×10^5) in 35 6-well plates. After 1 hour incubation at room temperature, cells were washed with PBS and incubated in growth medium for 24 hours. Viral infection was evaluated by X-Gal Staining.

Figure 7. Antibody-dependent infectivities of recombinant Sindbis virus particles on suspension cells Daudi and HL-60. Viral supernatants (500 μ l) derived from DH-BB and DH-BB-ZZ transfected BHK cells were preincubated without or with 0.5 μ g/ml of mAbs (anti-HLA-DR for Daudi and anti-CD33 for HL-60) at room temperature for 1 hour, and added to cells (1×10^6) in 6-well plates. After 1 hour incubation at room temperature, cells were washed with PBS and incubated in growth medium for 24 hours. Control shows uninfected cells.

10 Viral infection was evaluated by FACS-Gal analysis described in Experimental protocol. Positive percent of infected cells were shown in each panel.

5. DETAILED DESCRIPTION OF THE INVENTION

15 The present invention provides for a means for modifying the expression of genes in eukaryotic cells, such as mammalian cells or avian cells, and, more particularly, of human cells for medical practice and also of the cells of domesticated animals that are valuable for agriculture and recreational purposes for veterinary practice. The invention provides for the introduction and expression of genetic material into the cells by means of a viral vector complex. In the viral vector, some or all of the viral genes have been replaced by a gene that is to be expressed in the eukaryotic target cell. The essential viral genes that have been removed from the vector are, in general, inserted into the genome of the cell line that is used to produce stocks of the viral particles. The producer cells lines thus complement the defects that are present in the viral vector. In some embodiments, the only viral gene contained in the genome of the vector is a gene that is needed for the packaging of the vector genome into the viral particles.

Specifically, the invention is directed to viral vectors for transducing a target cell encoding a chimeric protein comprising an envelope protein and an IgG-binding domain of protein A. In one embodiment the envelope protein is a

retroviral envelope protein. An example of may be Moloney MLV envelope protein. In the envelope protein is inserted the IgG binding domain of protein A. As used herein, protein A may be a portion of native protein A or synthetic protein
5 having the Fc binding ability of native protein A. In one embodiment it is inserted into the hypervariable region of gp70.

In an alternative embodiment the envelope protein is an alphavirus envelope protein. An example of an alphavirus may
10 be a Sindbis virus. For the Sindbis virus it is preferable to insert the protein A into the E2 domain. The protein A is preferably inserted so as to reduce or minimize the non-specific infectivity of the Sindbis virus. One example of an insertion site is the position between amino acids 71 and 74
15 of the E2 glycoprotein.

The construction of viral-based vectors suitable for the general expression of genes in cells that are susceptible to infection by the virus is described the following patent publications: WO 89/05345 to Mulligan, R.C. and others, WO
20 92/07943 to Guild, B.C. and others concerning retroviral vectors; WO 90/09441 and WO 92/07945 to Geller, A.I. and others concerning herpes vectors; WO 94/08026 to Kahn, A. and others, and WO 94/10322 to Herz, J. and others concerning adeno virus vectors; U.S. Patent No. 5,354,678 to Lebkowski
25 and No. 5,139,941 to Muzyczka concerning adeno-associated virus; and U.S. Patent No. 5,217,879 to Huang et al. and No. 5,091,309 to Schlesinger concerning Sindbis viral vectors. Packaging systems for the production of retroviral vectors have been described by Danos, O. et al., 1988,
30 *Proc.Natl.Acad.Sci.* **85**:6460-64, and by Landau, N.R. et al., 1992, *J.Virol.* **66**:5110-13, the contents of the above are hereby incorporated by reference.

The complexes described herein can be provided with a variety of specificities. The application discloses methods
35 of constructing a complex comprising an antibody specific for an acceptor on the target cell so that the vector complex are internalized into the target cell after the vector complex is

bound. There are a large number of cell surface antigens suitable for use as acceptors and for which antibodies are already available. Such structures include, but are not limited to, the class I and class II Major Histocompatibility

5 Antigens; receptors for a variety of cytokines and cell-type specific growth hormones, brain derived neurotrophic factor (BDNF), ciliary neurotrophic factor (CTNF), colony stimulating growth factors, endothelial growth factors, epidermal growth factors, fibroblast growth factors, glially

10 derived neurotrophic factor, glial growth factors, growth factor, β -mip 2, hepatocyte growth factor, insulin-like growth factor, interferons (α -IFN, β -IFN, γ -IFN, consensus IFN), interleukins (IL-1, IL-2, IL-3, IL-4, IL-5, IL-6, IL-7, IL-8, IL-9, IL-10, IL-11, IL-12, IL-13, IL-14), keratinocyte growth

15 factor, leukemia inhibitory factors, macrophage/monocyte chemotactic activating factor, nerve growth factor, neutrophil activating protein 2, platelet derived growth factor, stem cell factor, transforming growth factor, tumor necrosis factors and vascular endothelial growth factor; cell

20 adhesion molecules; transport molecules for metabolites such as amino acids; the antigen receptors of B- and T-lymphocytes; and receptors for lipoproteins. The invention makes possible the specific infection of a cell type by allowing the employ of differentiation antigens as targets

25 for the viral vector complex.

The invention is used to transduce a gene of interest into a target cell. In practicing the preferred embodiment of the invention, the viral vector and the antibody are preincubated prior to contacting the target cell acceptor.

30 The practice of the invention can be performed by culturing the target cells *ex vivo*. The cultured cells can be continued in culture to produce the product encoded by the transduced gene. Alternatively, the *ex vivo* transduced cell can be implanted into a subject, which can be the host from

35 which the cultured cells were obtained.

In a yet further embodiment, the viral vector and appropriate antibodies can be administered directly to the

subject thereby obviating the need for any *ex vivo* cell culture. The routes of administration to the subject can be any route that results in contact between the vector complex and the target cell. Thus for example, intravenous
5 administration is suitable for target cells in the hepatic, splenic, renal cardiac and circulatory or hematopoietic systems. The vector complex can also be administered by catheterization of the artery or vein leading to the target organ, thereby allowing the localized administration of the
10 complex. The complex can also be administered by inspiration when the target cells are in the respiratory system.

Genes that can be transduced by the practice of the invention include any gene that can be expressed in a eukaryotic system. Illustrative examples of genes that can
15 be expressed by use of the present invention include glucocerebrosidase, adenosine deaminase, and blood coagulation factors such as factor VIII and factor IX.

The viral component of the vector complex can be based on any virus, the particles of which are unable to bind or
20 have been modified to be unable to bind to cells of the same species as the target cell. A non-limiting example of the virus are the murine ecotropic leukemia retrovirus viruses, e.g., Moloney Leukemia Virus or AKV. Alternatively, chemically modified viral particles can be employed. In
25 addition to ecotropic retroviruses, viruses that can be employed to construct vectors according to this embodiment of the invention include amphotropic retrovirus, herpes virus, adenovirus and adeno-associated virus. In addition, the viral component may be an alphavirus, such as a Sindbis
30 Virus.

The viral vectors and viral complexes of the invention may be used to treat a variety of disorders in man and animals. The vectors based on the Sindbis virus are particularly well suited for intracellular vaccination. That
35 is, the viral complex carries with it a gene of interest encoding a particular antigen. The viral complex will be taken up into the cell and the gene of interest encoding the

antigen is will be expressed in the cellular cytoplasm. By targeting the viral complex to desired cellular target, the antigen will be expressed within the cell of interest.

The complexes of this invention are also well suited for
5 the delivery of antisense sequences.

There are many examples of bacterial and viral diseases that may be prevented or ameliorated by the methods described herein. Specifically, the methods described herein may be used for the following diseases: adenovirus, AIDS, antibiotic
10 associated diarrhea, bacterial pneumonia, bovine herpes virus (BHV-1), chlamydia, croup, diphtheria, *Clostridium difficile*, cystitis, cytomegavirus (CMV), gastritis, gonorrhea, *heliobacter pylori*, hepatitis A, hepatitis B, herpes virus, HSV-1, HSV-2, human papilloma virus, influenza, legionnaires
15 disease, Lyme disease, malaria, multiple sclerosis, peptic ulcer, pertussis, psoriasis, rabies, respiratory syncytial virus (RSV), rheumatoid arthritis, rhinovirus, rotavirus, salmonella, Stomach cancer, strep throat, tetanus or travelers diarrhea.

20 The embodiments of the invention are described in greater detail hereinafter.

6. EXAMPLES

6.1. Example 1:

25

In this example we describe the construction of a recombinant ecotropic retrovirus displaying protein A-envelope chimeric proteins. Protein A, a protein derived from *Staphylococcus aureus*, has a strong affinity for the Fc
30 region of various mammalian IgGs (Surolia, A. et al., 1982, *Trends Biochem. Sci.* 7:74-76). Native protein A has five homologous IgG-binding domains (E, D, A, B and C) , and we have utilized the synthetic Z domain which is based on the B domain of protein A (Nilsson, B. et al., 1987, *Protein Eng.*
35 1:107-113). The development of retroviral vectors that can bind IgGs (monoclonal antibodies) would have important applications for specific gene delivery.

Materials and methods

6.1.1. Plasmids and Cell Line.

5 A SV40-based plasmid, p439 (SV-E-MLV-env), which express
Moloney MLV (Mo-MLV) envelope protein (Landau, N.R. et al.,
1992, *J. Virol.* 66:5110-5113), was kindly provided Dr. Dan R.
Littman, New York University. pEZZ 18, which contains two
10 synthetic Z domains based on the B domain of protein A
(Löwenadler, B. et al., 1987, *Gene* 58:87-97) was purchased
from Pharmacia Biotech, Uppsala, Sweden. pZeoSV, which has
Zeocin-resistant gene for selection, was purchased from
Invitrogen Co., San Diego, CA. An ecotropic retroviral
packaging cell line ψ 2 (ATCC CRL9560) (Mann, R. et al., 1983,
15 *Cell* 33:153-159) and COS-7 cells (ATCC CRL1651) were
maintained in Dulbecco's modified Eagle's medium (DMEM)
supplemented with 10% fetal bovine serum (FBS).

6.1.2. Construction of chimeric env gene.

20 Two synthetic IgG-binding domain of protein A (ZZ) were
amplified by polymerase chain reaction (PCR) using pEZZ 18 as
a template. Primers used for PCR amplification are ZZ-5 (5'-
CACGATGAGGTAACCGACAACAAATTCAAC-3') (SEQ ID NO. 1), with *Bst*
EII site, and M13 (-40) sequencing primer (5'-
25 GTTTTCCCAGTCACGAC-3') (SEQ ID NO. 2) which locates downstream
from the multiple cloning sites of pEZZ vector. The resulting
PCR products were digested with *Bst EII* and *Eco RI* and
replaced the Mo-MLV env gene between unique restriction sites
Bst EII (position 5923) and *Bam HI* (position 6537) of the
30 p439 vector in the presence of compatible oligonucleotides
EB1 (5'-AATTCGGGAGGCGGTGGATCAGGTGGAGGCGGTTTCAGG-3') (SEQ ID
NO. 3) and EB2 (5'-GATCCCTGAACCGCCTCCACCTGATCCACGCTCC-3')
(SEQ ID NO. 4) to act as a linker-spacer. Clones containing
35 inserts of proper size were sequenced to confirm that the
correct reading frames were maintained.

6.1.3. Cell transfection and virus production.

The wild-type and protein A-gp70 chimeric envelope genes were first transiently transfected into COS-7 cells. 2 x 10⁵ cells were seeded in 3.5 cm-diameter dishes and transfected the next day with 2 µg of plasmid with 10 µl of LipofectAmine reagent (Gibco-BRL, Gaithersburg, MD). 72 h after transfection, cells were collected and subjected to immunoblot analysis. To create packaging cell lines expressing the recombinant envelope, 5 x 10⁵ ψ2 cells were transfected with 20 µg of chimeric envelope plasmids and 1 µg of pZeoSV by the CaPO₄ method (Stratagene, La Jolla, CA) (Mann, R. et al., 1983). The medium was changed 16 hours later and transfected cells were selected with 250 µg/ml of Zeocin (Invitrogen Co., San Diego, CA) After selection for 10 days, Zeocin-resistant cell colonies were picked for expansion and screened by immunoblot analysis and ELISA as described below.

6.1.4. Immunoblot assay.

For monitoring of protein A-envelope chimeric protein expression, transfected cells and viral samples were subjected to immunoblot analysis. Virus samples were pelleted by ultracentrifugation of the supernatants (10 ml) in an SW41 Beckmann Rotor (25,000 rpm, 2 h, 4 °C). Immunoblot analysis was performed as described before (Marin, M. et al., 1996, *J. Virol.* 70:2957-2962) by using a goat antiserum against Rausher leukemia virus SU protein (Quality Biotech Inc., Camden, NJ) and horseradish peroxidase-conjugated rabbit anti-goat IgG antibodies (Pierce, Rockford, IL).

6.1.5. ELISA

ELISA was performed to detect chimeric virus carrying protein A-envelope chimeric protein in the culture supernatants. Briefly, pelleted viral particles from 10 ml culture supernatants were resuspended in 400 µl of phosphate

buffered saline. 96-well microtiter plates (Dynatech Laboratories, INC., Chantilly, VA) were coated with duplicate serial dilutions of viral samples for 2 h at RT followed by blocking with PBS containing 1 % BSA and 0.05 % Tween 20.

5 Then 0.1 μ g/ml of horseradish peroxidase-conjugated rabbit anti-goat IgG antibodies (Pierce) was added to each well and incubated for 2 h at RT. After washing with PBS containing 0.05 % Tween 20, the binding activity of each well was determined by using o-Phenylenediamine (Pierce) as a

10 substrate.

6.1.6. Results

Plasmid construction and transient expression in COS-7 cells

15 A modified Mo-MLV envelope expression vector, p439-ZZ, that would express two synthetic IgG-binding domain of protein A was generated (Fig. 1). The position of replacement in gp70 was previously shown to allow the functional display of erythropoietin (Kasahara, N. et al., 1994) and heregulin

20 (Han, X. et al., 1995, *Proc. Natl. Acad. Sci. USA* **92**:9747-9751). The C-terminus of the protein A gene is connected to a proline rich hypervariable region of gp70 with the EB linker-spacer (SGGGSGGGGS) (SEQ ID NO. 5) in order to avoid interactions between the IgG-binding part of protein A and

25 the envelope protein segment of the recombinant fusion protein. Expression is driven by the SV40 early enhancer/promoter sequence and the 5' long terminal repeat (LTR). The plasmid p-439-ZZ was deposited with the American Type Culture Collection (ATCC) on March 28, 1997.

30 To examine the expression of the recombinant envelope, we transfected p439-ZZ expression plasmid into COS-7 cells. Lysates from transfected and nontransfected cells were first analyzed for envelope expression by using anti-Rauscher leukemia virus SU serum which cross-reacts ecotropic (70 kDa)

35 Mo-MLV SU protein. As expected, the wild-type p439 plasmid expressed major protein bands of gp70 and its precursor (80 kDa) (Fig. 1B, lane 2). The recombinant p439-ZZ plasmid

expressed immunoreactive proteins at 70 kDa corresponding to precursor protein of the recombinant envelope suggesting that protein A-gp70 could be expressed in transfected COS cells. The same lysates were used for detection of IgG-binding activity using Horseradish peroxidase-conjugated rabbit anti-goat IgG. As shown in Fig. 1B, lane 6, the protein A-gp70 chimeric envelope precursor at 70 kDa expressed by p439-ZZ plasmid showed IgG-binding activity. Stable expression of the chimeric protein A-gp70 protein suggests that the protein A domain was properly folded after translation.

Creation of packaging cell lines producing protein A-envelope chimeric virus.

The chimeric envelope plasmid, p439-ZZ, and Zeocin-resistance gene were cotransfected into ψ 2 packaging cell line, which expresses gag, pol and env gene products of E-MLV. After selection with Zeocin, subclones were isolated and screened for protein A-gp70 expression by immunoblot analysis of whole cell lysate using rabbit IgG. One subclone, designated ψ 2-ZZ10, showed cytoplasmic IgG-binding activity and was chosen for further characterization. To demonstrate the incorporation of the chimeric envelope protein into virions, retroviral particles were purified by sucrose density gradient centrifugation. The viral pellets were then subjected to immunoblot analysis with anti-Rauscher leukemia virus SU serum or rabbit anti-goat IgG. Major bands of 70 kDa, which were derived from wild-type env gene of ψ 2 packaging cells, could be detected in both virions from ψ 2 and ψ 2-ZZ10 cells (Fig. 2A, lane 1 and 2). The band of 60 kDa, which was estimated MW of protein A-gp70 chimeric protein, was also detected in virions produced by ψ 2-ZZ10. However, less chimeric envelope was found in virus pellet compared with wild-type envelope. Virions produced by ψ 2-ZZ10 showed IgG-binding activity at the band of 60 kDa whereas there was no IgG-binding activity in that of untransfected ψ 2 cells (Fig. 2A, lane 3 and 4). The IgG-binding activity of chimeric virus was further confirmed by ELISA. As shown in Fig. 2B, the protein A-envelope chimeric virus produced by

ψ2-ZZ10 cells exhibited IgG-binding activity in a concentration dependent manner compared with that of untransfected ψ2 cells. Taken together, these results demonstrate that p439-ZZ produces recombinant retrovirus displaying the IgG-binding domain in its envelope.

6.1.7. Discussion

In this study we have shown that protein A can be displayed on the surface of murine ecotropic retroviral particles fused to the native envelope protein. The protein A-gp70 chimeric protein derived from p439-ZZ was correctly expressed and incorporated into virions. Furthermore, IgG-binding activity was detected in virions produced by ψ2-ZZ10 cells. In this study the chimeric envelope did not express as efficiently as that of wild type envelope in virions produced by ψ2-ZZ10 (Fig. 2A). We are currently trying to increase the expression of protein A-gp70 protein by changing the enhancer/promoter of the expression plasmid as well as utilizing other packaging cell lines.

The use of antibody-antigen interactions as the basis for targeting has a great advantage because a number of monoclonal antibodies have been developed and investigated. Since the protein A portion of the chimeric envelope binds to the Fc domain of the antibody (Surolia, A. et al., 1982), it allows flexibility with regard to the targeting elements, as any of a variety of mAbs can be selected. It has been reported that the binding of retrovirus-associated antibody fragments to the cell surface is followed by membrane fusion between virus and target cells (Etienne-Julan, M. et al., 1992, Roux, P. et al., 1989). The protein A-envelope chimeric retrovirus displaying mAbs against cell surface antigens should bind preferentially to target cells expressing those antigens, and this may facilitate their infection.

Furthermore, in principle, a similar approach may be used with other viral vectors, such as adenovirus and Sindbis virus vectors by inserting the synthetic IgG binding domain

(ZZ) of protein A. We also have constructed a recombinant Sindbis virus vector with protein A-envelope and demonstrated its high efficient cell-specific infection against variety of human cells, see Example 2. The protein A-envelope retroviral
5 vector as described in this example should also permit infection against specific cell types once the expression of chimeric envelope successfully increased in the virion. In conclusion, the novel cell targeting system which utilizes protein A-mAb interaction for virus infection would have
10 broad applications for gene expression studies and therapy.

6.2. Example 2:

In this example we describe the construction of a
15 recombinant Sindbis virus vector displaying protein A-envelope chimeric proteins to redirect the viral tropism. Protein A (PA), a protein derived from *Staphylococcus aureus*, has a strong affinity for the Fc region of various mammalian IgGs (Surolia, A. et al., 1982). In contrast to the targeted
20 retroviral vectors described above, the PA-envelope chimeric virus vector once successfully generated needs no further modification to target distinct cells. The targeting is achieved simply by changing the complementary mAb (Fig. 3A). More importantly, we demonstrate that this chimeric virus
25 used in conjunction with mAbs can infect human cells and transfer a test gene, bacterial β -galactosidase with high efficiency. The novel cell targeting system which utilizes PA-mAb interaction for virus infection would have important applications for gene expression studies and therapy.

30

6.2.1. Results

6.2.2. Construction of protein A-envelope Sindbis virus helper plasmid.

35 To modify the Sindbis virus envelope protein, we have utilized the DH-BB helper plasmid (Fig. 3B) which was constructed by deletion of the region between *Bsp*MII and

BamHI sites of the full-length Sindbis virus cDNA clone (Bredenbeek, P.J. et al., 1993, *J. Virol.* **67**:6439-6446). When RNA from DH-BB is cotransfected with recombinant RNA from the Sindbis virus expression vector (for example, 5 SinRep/LacZ, Fig. 3B), the structural proteins expressed in trans, from the DH-BB RNA transcript allows packaging of the recombinant RNA into virions. Since DH-BB does not contain a packaging signal, it will not form a defective interfering particle or be packaged with recombinant RNA. Two modified 10 Sindbis virus helper plasmids were constructed: DH-BB-Bst into which a BstEII cloning site was inserted and DH-BB-ZZ into which two IgG-binding domain of PA were inserted in the E2 region, were generated (Fig. 3B). Native protein A has five homologous IgG-binding domains (E, D, A, B and C) , and 15 we have utilized the synthetic Z domain which is based on the B domain of protein A (Nilsson, B. et al., 1987). The insertion position, between codons 71 and 74 amino acids in E2, was chosen because mutations in this region were previously shown to allow normal particle assembly and 20 release block virus entry at the level of attachment (Dubuisson, J. et al., 1993).

6.2.3. Expression and incorporation of chimeric envelopes into virions.

25 After linearization of helper and SinRep/LacZ plasmids, *in vitro* transcription was performed and the quality of RNA was checked on agarose gels (data not shown). To examine the expression of the recombinant envelope, recombinant helper RNA was cotransfected with RNA from SinRep/LacZ plasmid into 30 BHK cells by electroporation. The transfection efficiency was usually nearly 100 % under the procedure described in Experimental protocol below (data not shown). Lysates from transfected cells were first analyzed for expression of structural protein by using anti-Sindbis virus immune ascitic 35 fluid. As shown in Fig. 4A, DH-BB-Bst helper RNA expressed a 50 - 55 kDa band of envelope (E1 and E2) and a 33 kDa of

capsid protein which is the same protein profile as the parental virus produced by DH-BB. A band of 60 kDa corresponding to the E2 precursor PE2 was also detected. In the protein profile expressed by DH-BB-ZZ RNA, a major band 5 between 65 - 70 kDa, which is the estimated MW of PA-E2 and PA-PE2 chimeric protein, was observed as well as the 33 kDa capsid protein. These results suggest that the mutants were correctly expressed and processed. A band of envelope (E1) looks slightly shifted below in the lysate from DH-BB-ZZ 10 transfected cells due to the disappearance of E2 glycoprotein.

To demonstrate the incorporation of the chimeric envelope protein into virions, viral pellets were subjected to immunoblot analysis. As shown in Fig. 4B, virions produced 15 by DH-BB and DH-BB-Bst RNA contain capsid and envelope (E1 and E2) proteins indicating that the mutation in DH-BB-Bst does not affect virus assembly. The PA-E2 chimeric protein was also incorporated into virions and exhibited IgG-binding activity which is not detected in that of DH-BB and DH-BB-Bst 20 (Fig. 4B and C). These results demonstrate that DH-BB-ZZ produces recombinant Sindbis pseudovirions displaying the IgG-binding domain in its envelope. The protein band of E1, which was expressed in transfected cells (Fig. 4A, lane 3) could not be detected in the virions produced by DH-BB-ZZ 25 RNA.

6.2.4. Infection with viruses carrying mutant envelopes.

Infectivities of recombinant viruses against hamster and 30 human cells were determined by transfer of the Sindbis virus vector (SinRep/LacZ) that can transduce bacterial β -galactosidase gene. As shown in Table 1, viruses derived from DH-BB and DH-BB-Bst helper showed very high infectious titer (10⁸ LacZ CFU/ml) against BHK cells whereas viruses produced 35 by DH-BB-ZZ showed very low infectivity (10³ LacZ CFU/ml) suggesting that the protein A insertion into E2 blocked virus

binding to host cells supporting previous observations (Dubuisson, J. et al., 1993). The PA-envelope virus also showed minimal titer against human HeLa-CD4⁺ cells (10² LacZ CFU/ml). When virions were preincubated with anti-CD4 mAb, however, the protein A-envelope chimeric virus could infect HeLa-CD4⁺ cells in a antibody dose-dependent manner (Table 1). When the viral supernatant was preincubated with 0.5 µg/ml mAb, an infectious titer was approximately 10⁵ LacZ CFU/ml. The enhancement of infectivities by mAb was not observed with that of DH-BB and DH-BB-Bst derived viruses. As shown in Fig. 5, the protein A-envelope chimeric virus with anti-CD4 mAb could not infect HeLa cells which do not express CD4 on its surface indicating that the infection is dependent on both an antibody and a corresponding antigen. These data demonstrate that the PA-E2 chimeric envelope derived from DH-BB-ZZ helper RNA can redirect Sindbis virus infection via a new receptor/antigen in the presence of recognizing antibody.

Next, we determined whether PA-E2 displaying virus particles were capable of infection against various human cell lines expressing specific antigens on their surface. For adherent cells, epidermoid carcinoma cell line A431 and glioblastoma cell line U87MG, both overexpressing epidermal growth factor receptors (EGFR), were used. As expected, viruses with PA-envelope could infect these cells efficiently only when virions were preincubated with anti-EGFR mAb (Fig. 6). Infectious titers of the recombinant virus with mAb (0.5 µg/ml) against A431 and U87MG cells were approximately 10⁴ LacZ CFU/ml. Again, minimal infectivities (10² LacZ CFU/ml) were seen on these cells when infected without mAb. We next used two human suspension cell lines, Burkitt's lymphoma cells, Daudi, and promyelocytic leukemia cells, HL-60. In this experiment infected cells were detected by FACS-Gal analysis. Typical FACS results of infectivity are presented in Fig. 7. In contrast to the data with adherent cells (Fig. 6), the wild-type virus particles derived from DH-BB helper RNA have very low infectivities against Daudi and HL-60 cells. However, the PA-envelope virus preincubated with

corresponding mAbs (anti-HLA-DR for Daudi and anti-CD33 for HL-60) could infect these cells with very high efficiency, and the positive percent of infected cells were more than 90 % in both cell lines. Infection by the protein A-envelope virus of these cells was not observed in the absence of mAb.

6.2.5. Discussion

In this invention we describe the construction of a recombinant Sindbis virus vector displaying protein A-envelope chimeric proteins on the viral surface. The synthetic IgG-binding domain of protein A (ZZ) at the position between 71 and 74 amino acids of the E2 glycoprotein; this site has been shown to block Sindbis virus binding to host cells (Dubuisson, J. et al., 1993). The PA-E2 chimeric protein was correctly expressed and incorporated into Sindbis virions and exhibited IgG-binding activity as shown in Fig. 4B and C. In this experiment, however, the incorporation of E1 glycoprotein into virions could not be detected (Fig. 4C, lane 3) although it is expressed in transfected cells (Fig. 4A, lane 3). Insertion of the IgG-binding domain produces structural change of recombinant E2 chimeric protein that inhibits its interaction with E1 to form a heterodimer. The interaction between E1 and PA-E2 protein is not fully understood. This result also indicates that Sindbis virus assembly may occur without incorporation of the E1 glycoprotein. This observation may provide insight into mechanism of Sindbis virus assembly.

The PA-envelope chimeric Sindbis virus vector showed minimal infectivities against BHK and other human cell lines. However, when used in conjunction with mAbs which react with cell surface antigens, the PA-envelope chimeric virus was able to transfer the LacZ gene into human cell lines with high efficiency. The new tropism of the recombinant virus depends on antigen-antibody interaction since the PA-envelope virus could not infect targeted cells without mAb and corresponding antigen on cell surface (Fig. 5). Taken

together, the PA-E2 chimeric envelope derived from DH-BB-ZZ helper RNA can redirect Sindbis virus infection with high efficiency by antigen-antibody interaction.

Several retrovirus and adenovirus-based cell-targeting
5 vectors have been developed recently (Russell, S.J. et al.,
1993; Somia, N.V. et al., 1995; Marin, M. et al., 1996;
Douglas, J.T. et al., 1996, *Nature, Biotechnology* 14:1574-
1578). The novel cell-targeting system developed in this
study has some advantages compared with these retroviral and
10 adenoviral retargeting vectors. In this approach it is not
necessary to construct each targetable vector *de novo*. It is
unlikely that the incorporation of different targeting
elements in the envelope of the virus can always be achieved
with equal success and without reducing the virus titers that
15 could be obtained. Since the protein A portion of the
chimeric envelope binds to the Fc domain of the antibody
(Surolija, A. et al., 1982), it allows flexibility with
regards to the targeting elements, as any of a variety of
mAbs can be selected. In addition, replication occurs
20 entirely in the cytoplasm of the infected cells as an RNA
molecule, without a DNA intermediate (Strauss, J.H. et al.,
1994). This is in contrast to retrovirus vectors, which must
enter the nucleus and integrate into the host genome for
initiation of vector activity. Thus, retrovirus-derived
25 vectors have applications for long-term expression of foreign
proteins, while alphavirus vectors are useful primarily for
transient high-level expression. Furthermore, although
adenovirus vectors can express high levels of foreign
proteins, these systems are far more complex than
30 alphaviruses and express many highly antigenic virus-specific
gene products including structural proteins (Rosenfeld, M.A.
et al., 1991, *Science* 252:431-434). In contrast, current
alphavirus vectors express only the four viral replicase
proteins (nonstructural proteins nsP1 through nsP4) required
35 for RNA amplification in the transduced cells.

There are several issue which have to be considered in
working with Sindbis vectors. First, Sindbis virus infection

of vertebrate cells usually results in cell death by apoptosis (Levine, B. et al. 1993, *Nature* **361**:739-742), with the notable exception of neuronal cells in which a persistent infection may be established (Levine, B. et al. 1992, *J. Virol.* **66**:6429-6435). Although this cytotoxicity may be suitable for gene therapy for cancer, long-term or inducible expression vectors would have broader application. It has been reported that the transformation of cells with the cellular oncogene *bcl-2* led to a cell line in which Sindbis virus no longer induces apoptosis and instead establishes a persistent infection (Levine, B. et al., 1993; Levine, B. et al., 1996, *Proc. Natl. Acad. Sci. USA* **93**:4810-4815, the contents of which are hereby incorporated by reference into the present application). *bcl-2* may be used to construct a long-term Sindbis virus expression vector that overcomes the problems of apoptosis. The *bcl-2* vector would be particularly well suited to create a master packaging cell line also expressing the both chimeric Sindbis envelop protein and a heterologous gene of interest under the control of a Sindbis promoter. Second, the recombinant Sindbis virus vector developed in this invention may have low infectivities even in the absence of antibody. Accordingly, there might be other sites in E2 or E1 which are involved in receptor binding (Strauss, J.H. et al., 1994). Furthermore, different receptors have been identified on chicken embryo fibroblast (Wang, K.S. et al., *Virology* **181**:694-702) and mouse neuronal cells (Ubol, S. et al., 1991, *J. Virol.* **65**:6913-6921), suggesting that the Sindbis virus can utilize more than one receptor. For safety reason, it is desirable to develop improved recombinant Sindbis virus vector which do not infect any mammalian cells when not used with mAbs.

This invention represents the first demonstration of the retargeting of a Sindbis virus vector by a novel utilization of the protein A-antibody interaction. A similar approach may be used with other viral vectors, such as retrovirus and adenovirus vectors by inserting the synthetic IgG binding domain (ZZ) of protein A. The virus-based vectors displaying

for replicating the RNA transcript and the lacZ gene. Plasmid pEZZ 18, which contains two synthetic Z domains based on the B domain of protein A (Löwenadler, B. et al., 1987), was purchased from Pharmacia Biotech, Uppsala, Sweden. The
5 phagemid pALTER-1 vector (Promega Co. Madison, WI) was used to introduce the *Bst*EII site in E2 region of DH-BB plasmid by oligo-directed site-specific mutagenesis.

Construction of the recombinant Sindbis virus structural gene. Altered Sites *in vitro* Mutagenesis System (Promega Co.)
10 was used to introduce a specific restriction site into the E2 region of Sindbis virus structural gene. First, a *Bss*HII site was introduced between *Xba*I and *Hind*III sites of the pALTER-1 vector by using two compatible oligonucleotides 5'-CTAGAGCGCGCAAA-3' and 5'-AGCTTTTGCGCGCT-3' (SEQ ID NOS. 6-7).
15 A fragment between *Sac*I and *Bss*HII of the DH-BB plasmid containing the E2 region of structural gene was cloned into the pALTER-1 vector. A single-stranded template of the recombinant pALTER-1 vector was prepared by infection of helper phage M13K07. A mutagenic oligonucleotide (5'-
20 ATGTCGCTTAAGCAGGTAACCACCGTTAAAGAAGGC-3') (SEQ ID NO. 8) which introduces a *Bst*EII cloning site between codons 71 and 74 amino acids in E2 polypeptides and an ampicillin repair oligonucleotide (5'-GTTGCCATTGCTGCAGGCATCGTGGTG-3') (SEQ ID NO. 9) were annealed to the single-stranded template,
25 followed by synthesis of the mutant strand with T4 DNA polymerase. After transformation into *E. coli*, mutants were selected in the presence of ampicillin and screened by direct sequencing of the plasmid DNA. The *Sac*I-*Bss*HII region of original DH-BB plasmid was replaced with the mutated fragment
30 and the DH-BB-*Bst* plasmid was obtained (Fig. 3B). A region of protein A (ZZ) containing two synthetic IgG-binding domain was amplified by the polymerase chain reaction (PCR) using pEZZ 18 as a template. Primers used for PCR amplification are ZZ-5 (5'-CACGATGAGGTAACCGACAACAAATTCAAC-3') and ZZ-3 (5'-
35 GGTGCGAGGTTACCGGATCCCCGGGTACCGA-3') (SEQ ID NOS. 10-11) both encoding unique *Bst*EII sites. The resulting PCR products were digested with *Bst*EII and inserted into predigested DH-BB-*Bst*

plasmid at the *Bst*EII site. Clones containing inserts of proper size and orientation were sequenced to confirm that the correct reading frames were maintained and the DH-BB-ZZ plasmid was obtained (Fig. 3B). The plasmid p-DH-BB-ZZ was
5 deposited with the American Type Culture Collection (ATCC) on March 28, 1997.

In vitro transcription and transfection for recombinant virus production. Plasmids for in vitro transcription were
10 prepared by use of Qiagen (Chatsworth, CA) columns. All helper plasmids (DH-BB, DH-BB-Bst and DH-BB-ZZ) and SinRep/LacZ plasmid were linearized by *Xho*I restriction enzyme digestion and purified by phenol/chloroform extraction followed by ethanol precipitation. Transcription reactions
15 were carried out by using InvitroScript Cap Kit (Invitrogen Co.) to produce large quantities of capped mRNA transcript from the SP6 promoter. For cotransfections of helper and SinRep/LacZ RNA into BHK cells, electroporations were performed as described before (Liljeström, P. et al., 1991,
20 *Biotechnology* 9:1356-1361). Electroporated cells were transferred to 10 ml of α MEM containing 5 % FCS and incubated for 12 hours. Cells were then washed with PBS and incubated in 10 ml of Opti-MEM I medium (GIBCO-BRL) without FCS. After 24 hours, culture supernatants were harvested and aliquots
25 were stored at -80°C.

Immunoblot assay. Cells were lysed in 20 mM Tris-HCl buffer (pH 8.0) containing 1 % Triton X, 0.15 M NaCl, 1 mM phenylmethylsulfonyl fluoride, 1 mM EDTA and 10 % glycerol 24
hour after transfection. Cell extracts were then sonicated
30 and mixed with electrophoresis loading buffer (125 mM Tris-HCl, pH 6.8, 10 mM β -mercaptoethanol, 2 % SDS, 10 % glycerol and 0.01 % bromphenol blue). Virus samples were pelleted by ultracentrifugation of the supernatants (10 ml) in an SW41 Beckmann Rotor (35,000 rpm, 2 h, 4 °C) and resuspended in
35 electrophoresis loading buffer. Cell extracts and viral samples were subjected to immunoblot analysis as described before (Marin, M. et al., 1996) by using anti-Sindbis virus

mouse immune ascitic fluid (ATCC VR-1248) and horseradish peroxidase (HRP)-conjugated rabbit anti-goat IgG antibodies (Pierce, Rockford, IL).

Infection assays. Infectivity of recombinant chimeric
5 viruses to BHK and human cell lines was determined by transfer of the Sindbis virus vector (SinRep/LacZ) that can transduce the bacterial β -galactosidase gene (Bredenbeek, P.J. et al., 1993). Viral supernatant dilutions were incubated with or without monoclonal antibodies at room
10 temperature for 1 hour, then added to adherent (2×10^5) and suspension (1×10^6) cells in 6-well plates. After 1 hour incubation at room temperature, cells were washed with PBS and incubated in growth medium for 24 hours. Viral infection was evaluated by X-Gal Staining and FACS-Gal as described
15 below and titers were estimated in LacZ CFU per milliliter.

X-Gal Staining and FACS-Gal Assay. For X-gal staining, commercial protocol was followed. Briefly, cells were fixed in PBS containing 0.5% glutaraldehyde for 15 min followed by washing with PBS three times. Then cells were stained with
20 PBS containing 1 mg/ml X-gal, 5 mM potassium ferricyanide, 5 mM potassium ferrocyanide and 1 mM MgSO_4 at 37°C for 2 hours. The FACS-Gal assays were performed as described previously (Fiering, S.N. et al., 1991, *Cytometry* 12:291-301).

The present invention is not to be limited in scope by
25 the specific embodiments described which were intended as single illustrations of individual aspects of the invention, and functionally equivalent methods and components were within the scope of the invention. Indeed, various modifications of the invention, in addition to those shown
30 and described herein will become apparent to those skilled in the art from the foregoing description and accompanying drawings. Such modifications are intended to fall within the scope of the appended claims.

35

7. DEPOSIT OF MICROORGANISMS

The following organisms were deposited with the American Type Culture Collection (ATCC), 12301 Parklawn Drive, Rockville, Maryland 20852 on March 28, 1997.

<u>5 Strain Designation</u>	<u>Containing</u>	<u>Accession No.</u>
p-439-ZZ	Expression plasmid	
p-DH-BB-ZZ	Expression plasmid	

10

15

20

25

30

35

8. SEQUENCE LISTING

SEQUENCE LISTING

(1) GENERAL INFORMATION

- 5 (i) APPLICANT: Meruelo, Daniel
Ohno, Kouichi
- (ii) TITLE OF THE INVENTION: VIRAL VECTORS COMPLEXES HAVING
CHIMERIC ENVELOPE PROTEIN CONTAINING THE IgG-BINDING DOMAIN OF PROTEIN A
- (iii) NUMBER OF SEQUENCES: 11
- 10 (iv) CORRESPONDENCE ADDRESS:
(A) ADDRESSEE: Pennie & Edmonds
(B) STREET: 1155 Avenue of the Americas
(C) CITY: New York
(D) STATE: NY
(E) COUNTRY: USA
(F) ZIP: 10036/2711
- 15 (v) COMPUTER READABLE FORM:
(A) MEDIUM TYPE: Diskette
(B) COMPUTER: IBM Compatible
(C) OPERATING SYSTEM: DOS
(D) SOFTWARE: FastSEQ Version 2.0
- (vi) CURRENT APPLICATION DATA:
(A) APPLICATION NUMBER:
(B) FILING DATE: 28-MAR-1997
(C) CLASSIFICATION:
- 20 (viii) ATTORNEY/AGENT INFORMATION:
(A) NAME: Poissant, Brian M.
(B) REGISTRATION NUMBER: 28,462
(C) REFERENCE/DOCKET NUMBER: 8105-009
- (ix) TELECOMMUNICATION INFORMATION:
(A) TELEPHONE: 212-790-9090
(B) TELEFAX: 212-869-8864
(C) TELEX: 66141 PENNIE

25

(2) INFORMATION FOR SEQ ID NO:1:

- (i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 30 base pairs
(B) TYPE: nucleic acid
(C) STRANDEDNESS: single
(D) TOPOLOGY: linear
- 30 (ii) MOLECULE TYPE: DNA
- (xi) SEQUENCE DESCRIPTION: SEQ ID NO:1:

CACGATGAGG TAACCGACAA CAAATTCAAC

30

(2) INFORMATION FOR SEQ ID NO:2:

- 35 (i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 17 base pairs
(B) TYPE: nucleic acid
(C) STRANDEDNESS: single
(D) TOPOLOGY: linear

(ii) MOLECULE TYPE: DNA

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:2:

GTTTTCCCAG TCACGAC 17

(2) INFORMATION FOR SEQ ID NO:3:

5 (i) SEQUENCE CHARACTERISTICS:

(A) LENGTH: 38 base pairs

(B) TYPE: nucleic acid

(C) STRANDEDNESS: single

(D) TOPOLOGY: linear

(ii) MOLECULE TYPE: DNA

10 (xi) SEQUENCE DESCRIPTION: SEQ ID NO:3:

AATTCGGGAG GCGGTGGATC AGGTGGAGGC GGTTCAGG 38

(2) INFORMATION FOR SEQ ID NO:4:

(i) SEQUENCE CHARACTERISTICS:

(A) LENGTH: 36 base pairs

(B) TYPE: nucleic acid

15 (C) STRANDEDNESS: single

(D) TOPOLOGY: linear

(ii) MOLECULE TYPE: DNA

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:4:

GATCCCTGAA CCGCCTCCAC CTGATCCACC GCCTCC 36

(2) INFORMATION FOR SEQ ID NO:5:

20 (i) SEQUENCE CHARACTERISTICS:

(A) LENGTH: 11 amino acids

(B) TYPE: amino acid

(C) STRANDEDNESS: unknown

(D) TOPOLOGY: unknown

(ii) MOLECULE TYPE: protein

25 (xi) SEQUENCE DESCRIPTION: SEQ ID NO:5:

Ser Gly Gly Gly Gly Ser Gly Gly Gly Gly Ser

1 5 10

(2) INFORMATION FOR SEQ ID NO:6:

30 (i) SEQUENCE CHARACTERISTICS:

(A) LENGTH: 14 base pairs

(B) TYPE: nucleic acid

(C) STRANDEDNESS: single

(D) TOPOLOGY: linear

(ii) MOLECULE TYPE: DNA

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:6:

35 CTAGAGCGCG CAAA 14

(2) INFORMATION FOR SEQ ID NO:7:

(i) SEQUENCE CHARACTERISTICS:

(A) LENGTH: 14 base pairs
 (B) TYPE: nucleic acid
 (C) STRANDEDNESS: single
 (D) TOPOLOGY: linear

(ii) MOLECULE TYPE: DNA

5 (xi) SEQUENCE DESCRIPTION: SEQ ID NO:7:
 AGCTTTTGCG CGCT 14

(2) INFORMATION FOR SEQ ID NO:8:

(i) SEQUENCE CHARACTERISTICS:
 (A) LENGTH: 36 base pairs
 (B) TYPE: nucleic acid
 10 (C) STRANDEDNESS: single
 (D) TOPOLOGY: linear

(ii) MOLECULE TYPE: DNA

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:8:
 ATGTCGCTTA AGCAGGTAAC CACCGTTAAA GAAGGC 36

15 (2) INFORMATION FOR SEQ ID NO:9:

(i) SEQUENCE CHARACTERISTICS:
 (A) LENGTH: 27 base pairs
 (B) TYPE: nucleic acid
 (C) STRANDEDNESS: single
 (D) TOPOLOGY: linear

(ii) MOLECULE TYPE: DNA

20 (xi) SEQUENCE DESCRIPTION: SEQ ID NO:9:
 GTTGCCATTG CTGCAGGCAT CGTG GTG 27

(2) INFORMATION FOR SEQ ID NO:10:

(i) SEQUENCE CHARACTERISTICS:
 (A) LENGTH: 30 base pairs
 25 (B) TYPE: nucleic acid
 (C) STRANDEDNESS: single
 (D) TOPOLOGY: linear

(ii) MOLECULE TYPE: DNA

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:10:
 CACGATGAGG TAACCGACAA CAAATTCAAC 30

30 (2) INFORMATION FOR SEQ ID NO:11:

(i) SEQUENCE CHARACTERISTICS:
 (A) LENGTH: 30 base pairs
 (B) TYPE: nucleic acid
 (C) STRANDEDNESS: single
 (D) TOPOLOGY: linear

(ii) MOLECULE TYPE: DNA

35 (xi) SEQUENCE DESCRIPTION: SEQ ID NO:11:
 GGTCGAGGTT ACCGGATCCC CGGGTACCGA 30

WE CLAIM:

1. A viral vector for transducing a target cell which comprises a gene encoding a chimeric envelope protein
5 containing a portion of an IgG-binding domain of protein A in which the envelope protein is a viral envelope protein or fragment thereof and wherein the envelope protein or the fragment is operable to direct the assembly of the fragment into a viral particle.
- 10 2. The viral vector of claim 1, wherein the viral envelope protein comprises a portion of a retroviral envelope protein.
- 15 3. The viral vector of claim 2, wherein the viral envelope protein further comprises a portion of a gp70 protein of a ecotropic murine leukemia virus or an avian leukemia virus.
- 20 4. The viral vector of claim 3, wherein the chimeric envelope protein consisting essentially of a fusion protein of the gp70 protein and the IgG-binding domain of protein A.
- 25 5. The viral vector of claim 4, wherein the viral vector is p439-ZZ.
6. The viral vector of claim 1, wherein the viral envelope protein comprises a portion of an alphavirus envelope protein.
- 30 7. The viral vector of claim 6, wherein the alphavirus envelope protein comprises a portion of a Sindbis virus envelope protein.
- 35 8. The viral vector of claim 7, wherein the portion of the IgG binding domain of Protein A is inserted into an E2 glycoprotein of the Sindbis virus envelope protein.

9. The viral vector of claim 8, wherein the chimeric gene encodes a protein consisting essentially of a fusion protein of an E2 glycoprotein of the Sindbis virus envelope protein and the IgG-binding domain of protein A.

5

10. The viral vector of claim 9, wherein the viral vector is DH-BB-ZZ.

11. A viral vector for transducing a target cell which
10 comprises a gene encoding a chimeric envelope protein in which the envelope protein is an alphavirus envelope protein or fragment thereof, wherein the envelope protein or the fragment is operable to direct the assembly of the fragment into a viral particle and the chimeric envelop protein is
15 capable of directing the viral particle to a specific cellular receptor.

12. The viral vector of claim 11, wherein the chimeric envelop protein comprises a cytokine or a portion thereof.

20

13. The viral vector of claim 12, wherein the cytokine is selected from the group consisting of brain derived neurotrophic factor, ciliary neurotrophic factor, colony stimulating growth factors, endothelial growth factors,
25 epidermal growth factors, fibroblast growth factors, glially derived neurotrophic factor, glial growth factors, gro-beta/mip 2, hepatocyte growth factor, insulin-like growth factor, interferons, interleukins, keratinocyte growth factor, leukemia inhibitory factors, macrophage/monocyte
30 chemotactic activating factor, nerve growth factor, neutrophil activating protein 2, platelet derived growth factor, stem cell factor, transforming growth factor, tumor necrosis factors and vascular endothial growth factor.

14. The viral vector of claim 13, wherein the cytokine is a transforming growth factor.

15. The viral vector of claim 13, wherein the cytokine is IL-2.

16. The viral vector of claim 11, wherein the chimeric envelop protein comprises a portion of a streptavidin molecule.

17. The viral vector of claim 11, wherein the chimeric envelop protein comprises a portion of an antibody molecule.

10

18. A viral complex which comprises a gene of interest under the control of an appropriate viral sequence and a chimeric protein comprising a chimeric envelope protein containing a portion of an IgG-binding domain of protein A.

15

19. The viral complex of claim 18, wherein the IgG binding domain is expressed on the surface of the envelope protein.

20

20. The viral complex of claim 18 wherein the complex further comprises an antibody targeting a particular cell of interest.

21. The viral complex of claim 20 wherein the antibody binds to a receptor for a cytokine, which cytokine is selected from the group consisting of brain derived neurotrophic factor, ciliary neurotrophic factor, colony stimulating growth factors, endothelial growth factors, epidermal growth factors, fibroblast growth factors, glially derived neurotrophic factor, glial growth factors, gro-beta/mip 2, hepatocyte growth factor, insulin-like growth factor, interferons, interleukins, keratinocyte growth factor, leukemia inhibitory factors, macrophage/monocyte chemotactic activating factor, nerve growth factor, neutrophil activating protein 2, platelet derived growth factor, stem cell factor, transforming growth factor, tumor necrosis factors and vascular endothelial growth factor.

22. The viral complex of claim 20 in which the antibody binds an antigen which is selected from the group consisting of class I MHC antigens, class II MHC antigens, internalizing cell-surface receptors and viral receptors.

5

23. A viral complex which comprises a gene of interest under the control of an appropriate viral sequence and a chimeric alphavirus envelope protein.

10 24. The viral complex of claim 23, wherein the chimeric alphavirus envelope protein is a Sindbis virus envelope protein.

25. The viral complex of claim 24, wherein the
15 appropriate viral sequence is a Sindbis viral sequence.

26. The viral complex of claim 25, wherein the Sindbis viral sequence comprises a portion of the nsP1-4 sequence.

20 27. A packaging cell which comprises the viral vector of claim 1.

28. The packaging cell of claim 27, wherein the virus is an alphavirus and the packaging cell further comprises a
25 heterologous gene encoding *bcl-2*.

29. The packaging cell of claim 27, wherein the packaging cell is an ecotropic cell.

30 30. The packaging cell of claim 28, wherein the packaging cell is an ecotropic cell.

31. The packaging cell of claim 27, wherein the ecotropic packaging cell is a ψ 2 packaging cell.

35

32. A packaging cell which comprises the viral vector of claim 11.

33. The packaging cell of claim 32, wherein the packaging cell further comprises a heterologous gene encoding *bcl-2*.

5 34. The packaging cell of claim 32, wherein the packaging cell is an ecotropic cell.

35. The packaging cell of claim 33, wherein the packaging cell is an ecotropic cell.

10

36. The packaging cell of claim 32, wherein the ecotropic packaging cell is a $\psi 2$ packaging cell.

37. The packaging cell of claim 32, wherein the
15 packaging cell is an amphotropic cell.

38. A method of expressing a gene of interest in a target cell which comprises the steps of

- 20 a. forming a viral vector complex comprising:
- 1) a gene of interest operably linked to a promoter which is active in the target cell, and
 - 2) a chimeric protein comprising an envelope protein and an IgG-binding domain of Protein A; and
- 25 b. contacting the viral complex with the target cell in the presence of an appropriate antibody;

wherein the contacting takes place under suitable conditions so that the viral complex is internalized into the cell wherein the envelope protein is a viral envelope protein or
30 fragment thereof and wherein the envelop protein or the fragment is operable to direct the assembly of the fragment into the viral particle.

39. The method of claim 38, wherein the viral envelope
35 protein comprises a portion of a retroviral protein.

40. The method of claim 38, wherein the chimeric protein consists essentially of a fusion protein having a gp70 protein and the IgG-binding domain of Protein A.

5 41. The method of claim 38, wherein the envelope protein comprises a portion of an alphavirus envelope protein.

42. The method of claim 41, wherein the alphavirus envelope protein is a Sindbis virus envelope protein.

10

43. The method of claim 38, wherein the IgG binding domain of Protein A is inserted into an E2 glycoprotein of the Sindbis virus envelope protein.

15 44. The method of claim 38, wherein the chimeric gene encodes a protein which consists essentially of a fusion protein of the E2 glycoprotein of the Sindbis virus envelope protein and the IgG-binding domain of protein A.

20 45. The method of claim 38, wherein the viral complex is preincubated with the appropriate antibody.

46. The method of claim 38, wherein the target cell is a target cell cultured *ex vivo*.

25

47. The method of claim 38, wherein the target cell is a target cell present in a mammalian animal.

30

35

Abstract

The invention involves viral vectors that can be used to transduce a target cell, i.e., to introduce genetic material into the cell. The targets of interest are eukaryotic cells and particularly human cells. The transduction can be done *in vivo* or *in vitro*. More particularly the invention concerns viral vectors that have chimeric envelope proteins and contain the IgG-binding domain of protein A. These vectors when used in conjunction with antibodies targeting a particular cell are particularly useful for gene therapy.

15


20

25

30

35

Fig 7
1/6







Fig 2
2/6

3/6

Fig 3A

A




Fig 3B

B




Fig 4A-4C
4/6.




Fig 5
5/6





Fig 6
6/6



**DECLARATION
AND POWER OF ATTORNEY**

As a below named inventor, I hereby declare that:

My residence, post office address and citizenship are as stated below at 201 et seq. underneath my name.

I believe I am the original, first and sole inventor if only one name is listed at 201 below, or an original, first and joint inventor if plural names are listed at 201 et seq. below, of the subject matter which is claimed and for which a patent is sought on the invention entitled

VIRAL VECTORS HAVING CHIMERIC ENVELOPE PROTEINS CONTAINING THE IgG-BINDING DOMAIN OF PROTEIN A

and for which a patent application:

- ☒ is attached hereto and includes amendment(s) filed on _____ (if applicable)
☐ was filed in the United States on _____ as Application No. _____ (for declaration not accompanying application)
with amendment(s) filed on _____ (if applicable)
☐ was filed as PCT international Application No. _____ on _____ and was amended under PCT Article 19 on _____ (if applicable)

I hereby state that I have reviewed and understand the contents of the above identified application, including the claims, as amended by any amendment referred to above.

I acknowledge the duty to disclose information known to me to be material to patentability as defined in Title 37, Code of Federal Regulations, §1.56.

I hereby claim foreign priority benefits under Title 35, United States Code, §119(a)-(d) of any foreign application(s) for patent or inventor's certificate listed below and have also identified below any foreign application for patent or inventor's certificate having a filing date before that of the application on which priority is claimed:

EARLIEST FOREIGN APPLICATION(S), IF ANY, FILED PRIOR TO THE FILING DATE OF THE APPLICATION			
APPLICATION NUMBER	COUNTRY	DATE OF FILING (day, month, year)	PRIORITY CLAIMED
			YES <input type="checkbox"/> NO <input type="checkbox"/>
			YES <input type="checkbox"/> NO <input type="checkbox"/>

I hereby claim the benefit under Title 35, United States Code, §119(e) of any United States provisional application(s) listed below.

APPLICATION NUMBER	FILING DATE



I hereby claim the benefit under Title 35, United States Code, §120 of any United States application(s) listed below and, insofar as the subject matter of each of the claims of this application is not disclosed in the prior United States application in the manner provided by the first paragraph of Title 35, United States Code §112, I acknowledge the duty to disclose information which is material to patentability as defined in Title 37, Code of Federal Regulations, §1.56 which became available between the filing date of the prior application and the national or PCT international filing date of this application:

APPLICATION SERIAL NO.	FILING DATE	STATUS		
		PATENTED	PENDING	ABANDONED

POWER OF ATTORNEY: As a named inventor, I hereby appoint S. Leslie Misrock (Reg. No. 18872), Harry C. Jones, III (Reg. No. 20280), Berj A. Terzian (Reg. No. 20060), Gerald J. Flintoft (Reg. No. 20823), David Weild, III (Reg. No. 21094), Jonathan A. Marshall (Reg. No. 24614), Barry D. Rein (Reg. No. 22411), Stanton T. Lawrence, III (Reg. No. 25736), Isaac Jarkovsky (Reg. No. 22713), Joseph V. Colaiaanni (Reg. No. 20019), Charles E. McKenney (Reg. No. 22795), Philip T. Shannon (Reg. No. 24278), Francis E. Morris (Reg. No. 24615), Charles E. Miller (Reg. No. 24576), Gidon D. Stern (Reg. No. 27469), Stephen John J. Lauter, Jr. (Reg. No. 27814), Brian M. Poissant (Reg. No. 28462), Brian D. Coggio (Reg. No. 27624), Rory J. Radding (Reg. No. 28749), Stephen J. Harbulak (Reg. No. 29166), Donald J. Goodell (Reg. No. 19766), James N. Palik (Reg. No. 25510), Thomas E. Friebe (Reg. No. 29258), Laura A. Coruzzi (Reg. No. 30742), Jennifer Gordon (Reg. No. 30753), Jon R. Stark (Reg. No. 30111), Allan A. Fanucci (Reg. No. 30256), Geraldine F. Baldwin (Reg. No. 31232), Victor N. Balancia (Reg. No. 31231), Albert P. Halluin (Reg. No. 25227), Samuel B. Abrams (Reg. No. 30605), Steven I. Wallach (Reg. No. 35402), Marcia H. Sundeen (Reg. No. 30893), Paul J. Zegger (Reg. No. 33821), Edmond R. Bannon (Reg. No. 32110), Bruce J. Barker (Reg. No. 33291), Adriane M. Antler (Reg. No. 32605), Ann L. Gisolfi (Reg. No. 31956), SaraLynn Mandel (Reg. No. 31853), Mark A. Farley (Reg. No. 33170), James G. Markey (Reg. No. 31636), and Charles F. Hoyng (Reg. No. 35548), all of Pennie & Edmonds LLP, whose addresses are 1155 Avenue of the Americas, New York, New York 10036, 1667 K Street N.W., Washington, DC 20006 and 2730 Sand Hill Road, Menlo Park, CA 94025, and each of them, my attorneys, to prosecute this application, and to transact all business in the Patent and Trademark Office connected therewith.

SEND CORRESPONDENCE TO: PENNIE & EDMONDS LLP 1155 AVENUE OF THE AMERICAS NEW YORK, N.Y. 10036-2711				DIRECT TELEPHONE CALLS TO: PENNIE & EDMONDS LLP DOCKETING (212) 790-2803	
201	FULL NAME OF INVENTOR	LAST NAME Meruelo	FIRST NAME Daniel	MIDDLE NAME	
	RESIDENCE & CITIZENSHIP	CITY Scarborough	STATE OR FOREIGN COUNTRY New York	COUNTRY OF CITIZENSHIP U.S.A.	
	POST OFFICE ADDRESS	STREET 9 Country Club Lane	CITY Scarborough	STATE OR COUNTRY New York	ZIP CODE 10510
202	FULL NAME OF INVENTOR	LAST NAME Ohno	FIRST NAME Kouichi	MIDDLE NAME	
	RESIDENCE & CITIZENSHIP	CITY Kagoshima	STATE OR FOREIGN COUNTRY Japan	COUNTRY OF CITIZENSHIP Japan	
	POST OFFICE ADDRESS	STREET 1/22/15 Kamoike	CITY Kagoshima	STATE OR COUNTRY Japan	ZIP CODE 890
203	FULL NAME OF INVENTOR	LAST NAME	FIRST NAME	MIDDLE NAME	
	RESIDENCE & CITIZENSHIP	CITY	STATE OR FOREIGN COUNTRY	COUNTRY OF CITIZENSHIP	
	POST OFFICE ADDRESS	STREET	CITY	STATE OR COUNTRY	ZIP CODE
204	FULL NAME OF INVENTOR	LAST NAME	FIRST NAME	MIDDLE NAME	
	RESIDENCE & CITIZENSHIP	CITY	STATE OR FOREIGN COUNTRY	COUNTRY OF CITIZENSHIP	
	POST OFFICE ADDRESS	STREET	CITY	STATE OR COUNTRY	ZIP CODE
205	FULL NAME OF INVENTOR	LAST NAME	FIRST NAME	MIDDLE NAME	
	RESIDENCE & CITIZENSHIP	CITY	STATE OR FOREIGN COUNTRY	COUNTRY OF CITIZENSHIP	
	POST OFFICE ADDRESS	STREET	CITY	STATE OR COUNTRY	ZIP CODE
206	FULL NAME OF INVENTOR	LAST NAME	FIRST NAME	MIDDLE NAME	
	RESIDENCE & CITIZENSHIP	CITY	STATE OR FOREIGN COUNTRY	COUNTRY OF CITIZENSHIP	
	POST OFFICE ADDRESS	STREET	CITY	STATE OR COUNTRY	ZIP CODE

I hereby declare that all statements made herein of my own knowledge are true and that all statements made on information and belief are believed to be true; and further that these statements were made with the knowledge that willful false statements and the like so made are punishable by fine or imprisonment, or both, under Section 1001 of Title 18 of the United States Code and that such willful false statements may jeopardize the validity of the application or any patent issuing thereon.

SIGNATURE OF INVENTOR 201  Daniel Meruelo	SIGNATURE OF INVENTOR 202  Kouichi Ohno	SIGNATURE OF INVENTOR 203
DATE March 28, 1997	DATE March 28, 1997	DATE
SIGNATURE OF INVENTOR 204	SIGNATURE OF INVENTOR 205	SIGNATURE OF INVENTOR 206
DATE	DATE	DATE



PATENT

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Application of: Meruelo et al.

Serial No.: Not Yet Known

Group Art Unit:

Filed: Herewith

Examiner:

For: VIRAL VECTORS HAVING
CHIMERIC ENVELOPE
PROTEINS CONTAINING THE
IgG DOMAIN OF PROTEIN A

Attorney Docket No.: 8105-009

TRANSMITTAL OF SEQUENCE LISTING

Assistant Commissioner for Patents
Washington, D.C. 20231

Sir:

In connection with the application filed herewith,
Applicants submit herewith: a) Sequence Listings in paper and
computer readable form pursuant to 37 C.F.R. §1.821(c) and
(e), respectively.

I hereby state that the content of the computer
readable copy of the Sequence Listing and the Sequence in the
accompanying application are the same.

Respectfully submitted,

by *[Signature]* Reg. No. 36581
Brian M. Poissant
Brian M. Poissant 28,462
(Reg. No.)

Date March 28, 1997

PENNIE & EDMONDS LLP
1155 Avenue of the Americas
New York, New York 10036-2711
(212) 790-9090

Enclosures